We show that inhibition of the ErbB2-Par6 pathway was sufficient to block ErbB2-induced invasion, even in the presence of the second polarity gene loss, suggesting that developing ways to inhibit the ErbB2-Par6/aPKC pathway will open new avenues for blocking metastasis in ErbB2 positive cancers. This evidence concerns the gene ERBB2 and cancer.